Gut-Skin Axis Probiotic Composition for Atopic Dermatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis, such as topical corticosteroids and calcineurin inhibitors, are effective but come with significant adverse effects, and there is a need for safer, long-term alternatives that can effectively manage and prevent the condition.
Innovation Solution
A probiotic composition comprising Bifidobacterium lactis CECT 8145, Bifidobacterium longum CECT 7347, and Lactobacillus casei CECT 9104 is administered to modify the intestinal microbiota, improving the SCORAD index and reducing the need for corticosteroid use in patients with atopic dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical corticosteroids and calcineurin inhibitors are used to treat atopic dermatitis, then the effectiveness in managing the condition is improved, but significant adverse effects occur
Solution Approach 1:
The patent introduces probiotics as an intermediary substance that mediates the treatment of atopic dermatitis through the gut-skin axis. The probiotics modify intestinal microbiota composition, which in turn affects skin inflammation indirectly, avoiding the direct harmful effects of corticosteroids and calcineurin inhibitors on the skin while still achieving therapeutic effectiveness
Solution Approach 2:
The patent replaces the mechanical/chemical action of corticosteroids and calcineurin inhibitors (which directly suppress immune responses in the skin) with a biological approach using probiotics. The probiotics work through microbial modulation of the immune system via the gut-skin axis, substituting a different mechanism that avoids the adverse effects of direct immunosuppression
2Reliability
If probiotic composition is administered to modify intestinal microbiota, then the SCORAD index is significantly improved and corticosteroid use is reduced, but the mechanism involves complex immunological pathways
Solution Approach 1:
The patent segments the complex immunological pathway into distinct components: probiotic administration, intestinal microbiota modification, immune system modulation, and skin symptom improvement. This segmentation allows for targeted intervention at the gut level rather than attempting to directly manage complex skin immunology, simplifying the treatment approach while maintaining efficacy
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is intended for the use of a probiotic composition comprising Bifidobacterium animalis subs, lactis (B. lactis), Bifidobacterium longum and Lactobacillus casei, particularly the strains B. lactis CECT 8145, B. longum CECT 7347 and/or L. casei CECT 9104, in the treatment and/or prevention of atopic dermatitis.